Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus
February 22, 2019 7:32 AM ESTInsmed (NASDAQ: INSM) reported Q4 EPS of ($1.16), $0.10 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $6.89 million.
"2018 was a pivotal year for Insmed, with the U.S. approval and launch of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only FDA-approved treatment for patients with refractory Mycobacterium avium complex (MAC) lung disease. We are very pleased with the strong momentum we've seen since launch, including a wide breadth of prescribers, steady additions of new patients, and positive reimbursement trends," commented Will Lewis, Chairman... More
